Xcell Therapeutics Inc. (KOSDAQ:373110)

Xcell Therapeutics Statistics

Total Valuation

KOSDAQ:373110 has a market cap or net worth of KRW 20.71 billion. The enterprise value is 22.71 billion.

Market Cap	20.71B
Enterprise Value	22.71B

Important Dates

The last earnings date was Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

KOSDAQ:373110 has 10.94 million shares outstanding. The number of shares has increased by 20.42% in one year.

Current Share Class	10.94M
Shares Outstanding	10.94M
Shares Change (YoY)	+20.42%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	17.31%
Owned by Institutions (%)	0.08%
Float	7.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.94
PB Ratio	5.11
P/TBV Ratio	6.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.19
EV / Sales	15.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.49

Financial Position

The company has a current ratio of 1.04, with a Debt / Equity ratio of 1.40.

Current Ratio	1.04
Quick Ratio	0.73
Debt / Equity	1.40
Debt / EBITDA	n/a
Debt / FCF	-0.62
Interest Coverage	-2,337.10

Financial Efficiency

Return on equity (ROE) is -981.05% and return on invested capital (ROIC) is -88.50%.

Return on Equity (ROE)	-981.05%
Return on Assets (ROA)	-66.84%
Return on Invested Capital (ROIC)	-88.50%
Return on Capital Employed (ROCE)	-149.95%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.15
Inventory Turnover	3.02

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.28% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-57.28%
50-Day Moving Average	2,508.68
200-Day Moving Average	3,380.42
Relative Strength Index (RSI)	36.55
Average Volume (20 Days)	179,240

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOSDAQ:373110 had revenue of KRW 1.49 billion and -10.39 billion in losses. Loss per share was -953.65.

Revenue	1.49B
Gross Profit	-1.58B
Operating Income	-10.42B
Pretax Income	-10.39B
Net Income	-10.39B
EBITDA	-8.73B
EBIT	-10.42B
Loss Per Share	-953.65

Balance Sheet

The company has 3.66 billion in cash and 5.66 billion in debt, giving a net cash position of -2.00 billion or -182.88 per share.

Cash & Cash Equivalents	3.66B
Total Debt	5.66B
Net Cash	-2.00B
Net Cash Per Share	-182.88
Equity (Book Value)	4.05B
Book Value Per Share	370.12
Working Capital	223.04M

Cash Flow

In the last 12 months, operating cash flow was -8.04 billion and capital expenditures -1.06 billion, giving a free cash flow of -9.11 billion.

Operating Cash Flow	-8.04B
Capital Expenditures	-1.06B
Free Cash Flow	-9.11B
FCF Per Share	-832.42

Margins

Gross Margin	-106.58%
Operating Margin	-701.74%
Pretax Margin	-699.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KOSDAQ:373110 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.42%
Shareholder Yield	-20.42%
Earnings Yield	-50.16%
FCF Yield	-43.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOSDAQ:373110 has an Altman Z-Score of -5.74 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.74
Piotroski F-Score	2